ALK Brain NSCLC - Europe PMC

Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.

Introduction The aim of this paper was to determine the cost-effectiveness of alectinib and brigatinib in first-line for an anaplastic lymphoma mutation-positive advanced non-small cell lung cancer with an Aplastic lymphoma kinase mutation-positive advanced non-small cell lung cancer. Both alectinib and brigatinib are cost-effective treatments in first-line for ALK+ NSCLC, and in conclusion, combining pharmacological costs of drugs with the measure of effectiveness advocated by PFS.

Source link: https://europepmc.org/article/MED/34994227

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions